The PennZone

  • Home
  • Non-profit
  • Books
  • Entertainment
  • Music
  • Marketing
  • Health
  • Legal
  • Artificial Intelligence

MYONEX ANNOUNCES ACQUISITION OF SAVEWAY COMPOUNDING PHARMACY TO EXPAND ITS CLINICAL TRIAL SERVICES ACROSS THE US USA - English USA - español USA - English
The PennZone/10266682

Trending...
  • Growth Story Expands: $54.6M Contract, $30M Revenue Run Rate, 800+ Customers, 50+ Patents & New AI Cybersecurity Products for Cycurion, Inc $CYCU
  • Nutriband Inc. (N A S D A Q: NTRB) Breaks Into Uncharted Territory: 52-Week High Eclipsed as Shares Surge 22% —AVERSA™ Puts Investors on High Alert
  • Dr. Jay Johannigman Returns to Cincinnati Following 46 Years of Military Service
HORSHAM, Pa., April 9, 2024 ~ Myonex, a leading global clinical trial supply company, has recently announced the completion of its acquisition of SaveWay Compounding Pharmacy in Newark, Delaware. The pharmacy will now operate as SaveWay Compounding Pharmacy, a Myonex company.

This strategic move by Myonex is part of their ongoing efforts to support clinical trial sponsors' trial designs with direct-to-patient (DTP) and home healthcare provider (HHP) capabilities. With this acquisition, Myonex aims to provide wider patient access across the entire United States and support patients in obtaining the necessary trial medication and equipment.

According to James Lovett, Chief Executive Officer at Myonex, "SaveWay's pharmacy capabilities complement and extend our existing clinical supplies solutions within the US. SaveWay will provide additional access for drug sourcing and direct-to-patient options across all 50 states for our clinical packaging and labeling and ancillary supply services." This will also complement Myonex's market-leading CTRx™ to offer a full suite of prescription-based supply options for both investigational medicinal product (IMP) and commercial drug access throughout the US. These added capabilities will enable Myonex to better serve their clients' needs and facilitate decentralized clinical trials (DCT) and hybrid studies.

More on The PennZone
  • Harvard Educated Board Certified Endodontist Joins Pearlfection Dentistry
  • NYC Banners Delivers High-Stakes UN General Assembly Backdrop for the US Department of State Event
  • OneVizion Appoints Energy Infrastructure Executive Walt Farrell to Board of Directors
  • Tampa Bay Reporter Launches with a Mission to Deliver Local News with National Reach
  • "JACKIE the STRIPPER," Starring Charlotte Kirk and The PUSSYCAT DOLLS' Kimberly Wyatt, Now Streaming on PRIME

The acquisition also presents an opportunity for SaveWay to expand into the realm of clinical trials and accelerate the growth of their direct-to-patient services. Pradeep Chilakapati, RPh, Managing Partner and Pharmacist at SaveWay, expressed excitement about this partnership: "We welcome the opportunity to be part of an experienced clinical trial supply company with its roots in pharmacy. Myonex understands how we work and what we can offer to support today's trends in clinical trials."

This recent acquisition announcement comes on the heels of another significant acquisition by Myonex – that of Creapharm – further solidifying their commitment to providing faster, more flexible, and reliable services to their clients while improving the clinical trial patient experience. With these acquisitions, Myonex now boasts one of the most diverse clinical trial supply service offerings globally.

Myonex was exclusively advised by Crosstree as its financial advisor and Troutman Pepper as its legal advisor in this acquisition of SaveWay. This partnership is expected to bring about significant growth and success for both companies in the clinical trial supply industry.
Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Infinity Infusion Solutions Launches "Women Leading Infusion Care" Campaign for National Women in Business Month
  • HuskyTail Digital Puts AI to Work Behind the Scenes to Cut Client Turnaround Time
  • AI, Real-World Data "RWD" and U.S. Expansion Put Predictive Healthcare in Focus for POMDOCTOR Ltd. (N A S D A Q: POM)
  • $11.18 Million DARPA Award Ignites a Major New Catalyst as FDA, Robotic TMS and Commercialization Milestones Converge for NRx Pharmaceuticals, Inc
  • Dave's Auto Services Launches Free Seven-Week Fall Maintenance Series for Boyertown-Area Drivers
  • P-Wave Classics to publish Thomas Holcroft's The Adventures of Hugh Trevor in three volumes, beginning 19 January
  • Ad Leverage Sponsors ServiceTitan Pantheon 2026, Supporting Education and Growth in the Home Services Industry
  • From Newcomers to Neighbors: LINC Celebrates the People Who Make the Valley Home
  • Lehigh Valley's Kellyn Featured in National Film Series Exploring the Future of Diabetes Care
  • Top 100 Golf Coach Daniel Guest and Imagen Golf Announce Partnership with Remo Golf at Fairways Golf Club
  • DBF Viewer 2000 v9.32 Adds New Control for Data Export
  • Badanamu Partners With Moonbug Entertainment In Landmark Distribution Deal
  • Exonerated Movers Launches in Philadelphia on International Wrongful Conviction Day
  • Atlas Advisors President and Founder Mike McGuire Named a 2026 Leader in Business and Finance by LVB
  • Client 1st Financial Founder Michael Fischer Recognized for Building a Relationship-Rooted Career
  • Nutriband (N A S D A Q: NTRB): Fighting Back Against the Fentanyl Crisis With a New Approach to Safer Transdermal Medicines
  • Curtis Salgado shares a love letter to the city of Chicago and Otis Rush with new single
  • Oral statement on the situation of Chairman Lee Man-hee in pretrial detention in the Republic of Korea
  • Names Are Not Important Asks What Remains When Identity Is Stripped of Labels
  • UVIFY Brings Advanced Autonomous Systems Research to IROS 2026 in Pittsburgh

Popular on PennZone

  • Benny Turner Revisits Freddie King's Legacy for 50th Anniversary of His Passing - 248
  • Church Tradition Takes an Unexpected Turn at the Ford Community & Performing Arts Center - 215
  • GitKraken Names Jim Shaw CEO as Software Teams Move From AI Adoption to Multi-Agent Orchestration - 170
  • Brévant Guide Launches New National Restaurant Guide Across Canada - 139
  • VC Fast Pitch and Steamwork Ventures Bring Startup & Investor Networking Event to Santa Barbara on October 8 - 123
  • FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • SHI Introduces the RP-222B3S, Its Highest-Capacity 4K Pulse Tube Cryocooler
  • Sea Tales Strengthens U.S. Leadership Team as Retail Expansion Accelerates
  • Robert DeMaio, Phinge CEO to Speak at 30th IIPLA 2026 on Securing IP, User Data & Digital Sovereignty via Verified App-less Tech. Attend the Live Q&A!
  • Mandeville Pests May Pose Serious Health Risks for Your Family

Similar on PennZone

  • NIL Club Data Shows Brands Are Looking Beyond Follower Counts in College Sports
  • NYC Banners Delivers High-Stakes UN General Assembly Backdrop for the US Department of State Event
  • Genuine Hospitality, LLC Selected to Operate Fairfield Inn & Suites Tampa Wesley Chapel
  • Pregis to Highlight EPR Expertise, Sustainable Packaging Solutions and Live Automation Demonstrations at Pack Expo International 2026
  • Infinity Infusion Solutions Launches "Women Leading Infusion Care" Campaign for National Women in Business Month
  • HuskyTail Digital Puts AI to Work Behind the Scenes to Cut Client Turnaround Time
  • AI, Real-World Data "RWD" and U.S. Expansion Put Predictive Healthcare in Focus for POMDOCTOR Ltd. (N A S D A Q: POM)
  • $11.18 Million DARPA Award Ignites a Major New Catalyst as FDA, Robotic TMS and Commercialization Milestones Converge for NRx Pharmaceuticals, Inc
  • Nutriband (N A S D A Q: NTRB): Fighting Back Against the Fentanyl Crisis With a New Approach to Safer Transdermal Medicines
  • Most Utah Deaths Never Reach the Medical Examiner. Postmortem Pathology Offers Salt Lake City a Private Autopsy Option
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us